The DOI matches its Crossref record; 603 of the 603 references it cites were found in a registry or an index.
Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies
Open accessAbstract
The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which carry a risk for a disease progression and subsequent post-therapeutic relapse. Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. At the time point of tumor initiation, CSCs originate from either differentiated cells or adult tissue resident stem cells. Due to their importance, several biomarkers that characterize CSCs have been identified and correlated to diagnosis, therapy and prognosis. However, CSCs have been shown to display a high plasticity, which changes their phenotypic and functional appearance. Such changes are induced by chemo- and radiotherapeutics as well as senescent tumor cells, which cause alterations in the tumor microenvironment. Induction of senescence causes tumor shrinkage by modulating an anti-tumorigenic environment in which tumor cells undergo growth arrest and immune cells are attracted. Besides these positive effects after therapy, senescence can also have negative effects displayed post-therapeutically. These unfavorable effects can directly promote cancer stemness by increasing CSC plasticity phenotypes, by activating stemness pathways in non-CSCs, as well as by promoting senescence escape and subsequent activation of stemness pathways. At the end, all these effects can lead to tumor relapse and metastasis. This review provides an overview of the most frequently used CSC markers and their implementation as biomarkers by focussing on deadliest solid (lung, stomach, liver, breast and colorectal cancers) and hematological (acute myeloid leukemia, chronic myeloid leukemia) cancers. Furthermore, it gives examples on how the CSC markers might be influenced by therapeutics, such as chemo- and radiotherapy, and the tumor microenvironment. It points out, that it is crucial to identify and monitor residual CSCs, senescent tumor cells, and the pro-tumorigenic senescence-associated secretory phenotype in a therapy follow-up using specific biomarkers. As a future perspective, a targeted immune-mediated strategy using chimeric antigen receptor based approaches for the removal of remaining chemotherapy-resistant cells as well as CSCs in a personalized therapeutic approach are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CSCs are a subpopulation of tumor cells with the capacity for sustained self-renewal that, in turn, can not only drive tumor initiation but can also cause relapses, metastasis, and resistance to therapy [82,83].”
From 20-Hydroxyecdysone Confers Antioxidant and Antineoplastic Properties in Human Non-Small Cell Lung Cancer Cells (2023) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–600 of 603
Xie, L. H., Biondo, M., Busfield, S. J., Arruda, A., Yang, X., Vairo, G., & Minden, M. D. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.52 · Cited by 45
Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting
Ma, J., Zhuang, H., Zhuang, Z., Lu, Y., Xia, R., Gan, L., & Wu, Y. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1394874 · Cited by 45
CD90 promotes cell migration, viability and sphere‑forming ability of hepatocellular carcinoma cells
Zhang, K., Che, S., Su, Z., Zheng, S., Zhang, H., Yang, S., Li, W., & Liu, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3314 · Cited by 45
Diluvio, G., Gaudio, F. D., Giuli, M. V., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0051-9 · Cited by 45
Raspadori, D., Pacelli, P., Sicuranza, A., Abruzzese, E., Iurlo, A., Cattaneo, D., Gozzini, A., Galimberti, S., Baratè, C., Pregno, P., et al. (2019) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21764 · Cited by 45
Xiang, X., Yang, L., Zhang, X. Y., Ma, X., Miao, R., Gu, J., Fu, Y., Yao, Q., Zhang, J., Liu, C., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i14.1715 · Cited by 45
Lung adenocarcinoma subtypes based on expression of human airway basal cell genes
Fukui, T., Shaykhiev, R., Agosto-Perez, F., Mezey, J. G., Downey, R. J., Travis, W. D., & Crystal, R. G. (2013) · European Respiratory Journal · doi:10.1183/09031936.00144012 · Cited by 44
Ding, Q., Xia, Y., Ding, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7360 · Cited by 44
Seo, A. N., Lee, H. J., Kim, E. J., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.101 · Cited by 44
Wu, D., Mou, Y., Chen, K., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3551 · Cited by 44
Yamano, S., Gi, M., Tago, Y., Doi, K., Okada, S., Hirayama, Y., Tachibana, H., Ishii, N., Fujioka, M., Tatsumi, K., et al. (2015) · Cancer Science · doi:10.1111/cas.12855 · Cited by 44
Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness
Moro, M., Bertolini, G., Caserini, R., Borzi, C., Boeri, M., Fabbri, A., Leone, G., Gasparini, P., Galeone, C., Pelosi, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06912-7 · Cited by 44
A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia
Hoseini, S. S., Guo, H.-F., Wu, Z., Hatano, M. N., & Cheung, N. V. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014373 · Cited by 44
Zhou, L., & Zhu, Y. (2018) · International Journal of Surgery · doi:10.1016/j.ijsu.2018.06.025 · Cited by 44
Immune signature profiling identified prognostic factors for gastric cancer
Yang, W., Lai, Z., Li, Y., et al. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.03.08 · Cited by 44
Asymmetric division: a marker for cancer stem cells?
Bu, P., Chen, K., Lipkin, S. M., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1029 · Cited by 43
Ge, G., Zhou, C., Ren, Y. T., Tang, X., Wang, K., Zhang, W., Niu, L., Zhou, Y., Yu, Y., & He, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4226-0 · Cited by 43
Jin, J., Niu, X., Zou, L., Li, L., Li, S., Han, J., Zhang, P., Song, J., & Xiao, F. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.033 · Cited by 43
Characterization of cancer stem cells from different grades of human colorectal cancer
Manhas, J., Bhattacharya, A., Agrawal, S., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5232-6 · Cited by 43
Schneider, D., Xiong, Y., Hu, P., Wu, D., Chen, W., Ying, T., Zhu, Z., Dimitrov, D. S., Dropulić, B., & Orentas, R. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00539 · Cited by 43
The role of LGR5 and ALDH1A1 in non-small cell lung cancer: Cancer progression and prognosis
Gao, F., Zhou, B., Xu, J., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.029 · Cited by 42
Lgr5 expression is a valuable prognostic factor for colorectal cancer: evidence from a meta-analysis
Jiang, Y., Li, W., He, X., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1985-3 · Cited by 42
Correnti, M., & Raggi, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12569 · Cited by 42
Frolova, O., Benito, J., Brooks, C. L., Wang, R., Korchin, B., Rowinsky, E. K., Cortes, J. E., Kantarjian, H. M., Andreeff, M., Frankel, A. E., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12978 · Cited by 41
Zhao, Y., Peng, J., Zhang, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7054 · Cited by 41
Čulen, M., Borský, M., Némethová, V., Rázga, F., Šmejkal, J., Jurček, T., Dvořáková, D., Žáčková, D., Weinbergerová, B., Semerád, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9108 · Cited by 41
Xiang, Y., Yang, T., Pang, B.-Y., Zhu, Y., & Liu, Y. (2016) · Stem Cells International · doi:10.1155/2016/7614971 · Cited by 41
Homayouni, V., Ganjalıkhani-Hakemi, M., Rezaei, A., Khanahmad, H., Behdani, M., & Kazemi‐Lomedasht, F. (2016) · PubMed Central · doi:10.22038/ijbms.2016.7820 · Cited by 41
Sadovnik, I., Herrmann, H., Eisenwort, G., Blatt, K., Hoermann, G., Mueller, N., Sperr, W. R., & Valent, P. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.003 · Cited by 41
Liang, D.-S., Zhang, W., Wang, A.-T., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.022 · Cited by 41
Voeltzel, T., Flores-Violante, M., Zylbersztejn, F., Lefort, S., Billandon, M., Jeanpierre, S., Joly, S., Fossard, G., Milenkov, M., Mazurier, F., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1042-7 · Cited by 41
Oct4 Gene Expression in Primary Colorectal Cancer Promotes Liver Metastasis
Fujino, S., & Miyoshi, N. (2019) · Stem Cells International · doi:10.1155/2019/7896524 · Cited by 41
Su, R., Nan, H., Guo, H., Ruan, Z., Jiang, L., Song, Y., & Nan, K. (2016) · Hepatology Research · doi:10.1111/hepr.12687 · Cited by 40
Xie, X., Xie, X., Huang, X., et al. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009617666171024165657 · Cited by 40
Alamgeer, M., Watkins, D. N., Banakh, I., Kumar, B., Gough, D. J., Markman, B., & Ganju, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0555-8 · Cited by 40
Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma
Zhu, L., Zhang, W., Wang, J., & Liu, R. (2015) · Tumor Biology · doi:10.1007/s13277-015-3196-6 · Cited by 39
Jo, J. H., Park, S. B., Park, S., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030555 · Cited by 39
Bock, C., Kühn, C., Ditsch, N. C., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1750-z · Cited by 38
Wittwer, N. L., Brumatti, G., Marchant, C. L., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002931 · Cited by 38
Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
Huang, X., Huang, J., Leng, D., Yang, S., Qi, Y., Sun, J., & Hu, J. (2017) · World Journal of Surgical Oncology · doi:10.1186/s12957-017-1230-4 · Cited by 38
Seino, S., Tsuchiya, A., Watanabe, Y., Kawata, Y., Kojima, Y., Ikarashi, S., Yanai, H., Nakamura, K., Kumaki, D., Hirano, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25074 · Cited by 38
Noh, C., Wang, H. J., Kim, C. M., Kim, J.-P., Yoon, S. Y., Lee, G. H., Cho, H. J., Yang, M. J., Kim, S. S., Hwang, J. C., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12700 · Cited by 38
Nozaki, Y., Tamori, S., Inada, M., Katayama, R., Nakane, H., Minamishima, O., Onodera, Y., Abe, M., Shiina, S., Tamura, K., et al. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.148 · Cited by 38
Yuan, W., Yuan, Y., Zhang, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118799 · Cited by 37
SOX2 inhibits metastasis in gastric cancer
Chen, Y., Huang, Y., Zhu, L., Chen, M., Huang, Y., Zhang, J., He, S., Li, A., Chen, R., & Zhou, J. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2125-4 · Cited by 37
Nishino, M., Ozaki, M., Hegab, A. E., Hamamoto, J., Kagawa, S., Arai, D., Yasuda, H., Naoki, K., Soejima, K., Saya, H., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19732 · Cited by 37
Choi, G. H., Kim, G. I., Yoo, J. E., Na, D. C., Han, D. H., Roh, Y. H., Park, Y. N., & Choi, J. S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4480-9 · Cited by 36
Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer
Xi, H., Cui, J., Shen, W., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3207 · Cited by 36
The Clinical Significance of Cancer Stem Cell Markers ALDH1A1 and CD133 in Lung Adenocarcinoma
Miyata, T., Oyama, T., Yoshimatsu, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11597 · Cited by 36
Miller, T. J., McCoy, M. J., Hemmings, C., Bulsara, M. K., Iacopetta, B. M., & Platell, C. F. E. (2017) · Pathology · doi:10.1016/j.pathol.2017.08.007 · Cited by 36
CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer.
Lim, S. H., Jang, J., Park, J. O., et al. (2014) · PubMed · doi:10.3978/j.issn.2078-6891.2014.071 · Cited by 35
Prognostic value of circulating CD133 + cells in patients with gastric cancer
Pu, X., Song, C., Liu, J., Wang, D., & Xu, X. (2015) · Cell Proliferation · doi:10.1111/cpr.12175 · Cited by 35
Cheung, P. F., Cheung, T. T., Yip, C. W., Ng, L. W. C., Fung, S. W., Lo, C. M., Fan, S. T., & Cheung, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7803 · Cited by 35
Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro
Zhu, M., Li, W., Lu, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep26472 · Cited by 35
Chen, X., Chen, X., Wang, Y.-G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11384 · Cited by 35
Shu, X., Liu, H., Pan, Y., Sun, L., Yu, L., Sun, L., Yang, Z., & Ran, Y. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03548-1 · Cited by 35
Heterogeneity of Hepatic Cancer Stem Cells
Sukowati, C. H. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14366-4_4 · Cited by 35
Liu, R., Shen, Y., Nan, K., et al. (2015) · Medicine · doi:10.1097/md.0000000000001306 · Cited by 34
ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome
Breast Surgical Team at Outram, Tan, E. Y., Thike, A. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.297 · Cited by 34
Lee, S. Y., Kim, K.-A., Kim, C. H., Kim, Y. J., Lee, J.-H., & Kim, H. R. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3801 · Cited by 34
Yoshida, M., Yamashita, T., Okada, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11848-z · Cited by 34
Legge, D., Shephard, A. P., Collard, T. J., Greenhough, A., Chambers, A., Clarkson, R. W. E., Paraskeva, C., & Williams, A. C. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.037697 · Cited by 34
A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells
Zhou, S., Li, W., Xiao, Y., Zhu, X., Zhong, Z., Li, Q., Cheng, F., Zou, P., You, Y., & Zhu, X. (2020) · Leukemia · doi:10.1038/s41375-020-0824-y · Cited by 34
Braciak, T. A., Roskopf, C. C., Wildenhain, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1472195 · Cited by 33
Arai, N., Homma, M., Abe, M., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02616-y · Cited by 33
Fan, W., Wang, X., Ding, B., et al. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1077850 · Cited by 32
Shen, J., Wang, W., Zhu, X., et al. (2018) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.07.030 · Cited by 32
Hartman, M. L., Sztiller-Sikorska, M., & Czyż, M. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22953 · Cited by 32
The Presence of EpCAM-/CD49f+Cells in Breast Cancer Is Associated with a Poor Clinical Outcome
Ye, F., Qiu, Y., Li, L., Yang, L., Cheng, F., Zhang, H., Wei, B., Zhang, Z., Sun, L., & Bu, H. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.242 · Cited by 31
Wang, H., Liu, B., Wang, J., Li, J., Gong, Y., Li, S., Wang, C., Cui, B., Xue, X., Yang, M., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485405 · Cited by 31
de Moraes, J. K., Wagner, V. P., Fonseca, F. P., do Amaral‐Silva, G. K., de Farias, C. B., Pilar, E. F. S., Gregianin, L. J., Roesler, R., Vargas, P. A., & Martins, M. D. (2019) · Oral Diseases · doi:10.1111/odi.13190 · Cited by 31
JI, P., Zhang, Y., Wang, S., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.4739 · Cited by 30
Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1
Sizemore, G. M., Balakrishnan, S., Hammer, A. M., Thies, K., Trimboli, A. J., Wallace, J. A., Sizemore, S. T., Kladney, R. D., Woelke, S. A., Yu, L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.383 · Cited by 30
CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer
Ye, F., Zhong, X., Qiu, Y., Yang, L., Wei, B., Zhang, Z., & Bu, H. (2017) · Journal of Breast Cancer · doi:10.4048/jbc.2017.20.2.142 · Cited by 30
Brugnoli, F., Grassilli, S., Lanuti, P., Marchisio, M., Al‐Qassab, Y., Vezzali, F., Capitani, S., & Bertagnolo, V. (2017) · BMC Cancer · doi:10.1186/s12885-017-3592-y · Cited by 30
Piao, L., Feng, Y., Yang, Z., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152437 · Cited by 30
Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line.
Wang, X., Liu, Y., Zhou, K., et al. (2015) · PubMed · Cited by 29
Colnot, D. R., Ossenkoppele, G. J., Roos, J. C., Quak, J. J., de Bree, R., Börjesson, P. K. E., Huijgens, P. C., Snow, G. B., & van Dongen, G. A. M. S. (2002) · PubMed · Cited by 29
Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia
Lang, F., Wojcik, B., & Rieger, M. A. (2015) · Stem Cells International · doi:10.1155/2015/137164 · Cited by 29
Cui, J., Li, P., Liu, X., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.2942 · Cited by 29
Kim, S., & Singh, S. V. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3279-5 · Cited by 28
RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells
Gallo, M., Frezzetti, D., Roma, C., Chicchinelli, N., Barbieri, A., Arra, C., Scognamiglio, G., Botti, G., Luca, A. D., & Normanno, N. (2018) · Oncotarget · doi:10.18632/oncotarget.24784 · Cited by 28
Ojo, D., Lin, X., Wu, Y., Cockburn, J., Bane, A. L., & Tang, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.048 · Cited by 28
Aljabery, F. A.-S., Shabo, I., Gimm, O., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.05.025 · Cited by 28
Fallah, M., Mohammadi, H., Shaki, F., Hosseini‐khah, Z., Moloudizargari, M., Dashti, A., Ziar, A., Mohammadpour, A., Mirshafa, A., Modanloo, M., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116677 · Cited by 28
Implications of Epithelial–Mesenchymal Plasticity for Heterogeneity in Colorectal Cancer
Pereira, L. A., Mariadason, J. M., Hannan, R. D., & Dhillon, A. S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00013 · Cited by 27
Fan, D., Li, Z., Zhang, X., Yang, Y., Yuan, X., Zhang, X., Yang, M., Zhang, Y., & Xiong, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0109-5 · Cited by 27
Willmann, M., Sadovnik, I., Eisenwort, G., Entner, M., Bernthaler, T., Stefanzl, G., Hadzijusufovic, E., Berger, D., Herrmann, H., Hoermann, G., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.012 · Cited by 27
The POU5F1 gene expression in colorectal cancer: a novel prognostic marker
Miyoshi, N., Fujino, S., Ohue, M., Yasui, M., Takahashi, Y., Sugimura, K., Tomokuni, A., Akita, H., Kobayashi, S., Takahashi, H., et al. (2018) · Surgery Today · doi:10.1007/s00595-018-1644-9 · Cited by 27
Williams, B. A., Wang, X.-H., Leyton, J. V., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.187385 · Cited by 27
Сергеевна, З. Г., Kolovskaya, O. S., Ivanchenko, T. I., Zamay, T. N., Veprintsev, D. V., Grigorieva, V. L., Garanzha, I. V., Krat, A. V., Glazyrin, Y. E., Gargaun, A., et al. (2019) · Cancers · doi:10.3390/cancers11030351 · Cited by 27
Zahler, S. G., Bhatia, M., Ricci, A. M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.01.019 · Cited by 26
Gastric Stem Cell and Cellular Origin of Cancer
Hata, M., Hayakawa, Y., & Koike, K. (2018) · Biomedicines · doi:10.3390/biomedicines6040100 · Cited by 26
den Bossche, J. V., Deben, C., Pauw, I. D., Lambrechts, H. A. J., Hermans, C., Deschoolmeester, V., Jacobs, J., Specenier, P. M., Pauwels, P., Vermorken, J. B., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12477 · Cited by 26
Chen, D., Li, Z., Qian, C., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205769 · Cited by 26
Luo, J., Yan, R., He, X., & He, J. (2018) · PubMed Central · Cited by 26
Yevsa, T., Kang, T.-W., & Zender, L. (2012) · OncoImmunology · doi:10.4161/onci.19128 · Cited by 25
Self-citationVirtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cells
Aguirre-Alvarado, C., Segura‐Cabrera, A., Velázquez-Quesada, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8180 · Cited by 25
A system for detecting high impact-low frequency mutations in primary tumors and metastases
Anjanappa, M., Hao, Y., Simpson, E. R., et al. (2017) · Oncogene · doi:10.1038/onc.2017.322 · Cited by 25
CD133 mRNA may be a suitable prognostic marker for human breast cancer
Pu, X. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.10.03 · Cited by 25
Yabushita, T., Satake, H., Maruoka, H., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1410888 · Cited by 25
Galimberti, S., Grassi, S., Baratè, C., Guerrini, F., Ciabatti, E., Perutelli, F., Ricci, F., Genio, G. D., Montali, M., Barachini, S., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00555 · Cited by 25
Prognostic Value of Cancer Stem Cell Markers CD44 and ALDH1/2 in Gastric Cancer Cases
Şenel, F., Ünal, T., Karaman, H., et al. (2017) · PubMed · doi:10.22034/apjcp.2017.18.9.2527 · Cited by 24
Tos̆ić, N., Petrović, I., Kovačević‐Grujičić, N., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.02.001 · Cited by 24
New and emerging therapies for acute myeloid leukaemia
DAVIS, J. R., Benjamin, D. J., & Jonas, B. A. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000807 · Cited by 24
Survival outcomes of CD34+CD38−LSCs and their expression of CD123 in adult AML patients
Zahran, A. M., Aly, S. S., Rayan, A., El‐Badawy, O., Abdelfattah, M., Ali, A., ElBadre, H. M., & Hetta, . F. (2018) · Oncotarget · doi:10.18632/oncotarget.26118 · Cited by 24
Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo
Elango, R., Vishnubalaji, R., Manikandan, M., Binhamdan, S., Siyal, A., Alshawakir, Y. A., Alfayez, M. A., Aldahmash, A. M., & Alajez, N. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50140-0 · Cited by 24
Overexpression of PROM1 (CD133) confers poor prognosis in non-small cell lung cancer.
Qiu, Z.-X., Zhao, S., Mo, X., et al. (2015) · PubMed · Cited by 23
Huang, X., Li, D., Li, T., ZHAO, B., & Chen, X. (2015) · Oncology Letters · doi:10.3892/ol.2015.3189 · Cited by 23
Identification of AQP3 and CD24 as biomarkers for carcinogenesis of gastric intestinal metaplasia
Zhao, H., Wen, J., Dong, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18817 · Cited by 23
Zhang, C. C., Yan, Z., Pascual, B., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.008 · Cited by 23
Louhichi, T., Ziadi, S., Saad, H., et al. (2018) · Breast Cancer · doi:10.1007/s12282-018-0875-3 · Cited by 23
Yin, J., Tang, Q., Zhai, L.-L., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3731-5 · Cited by 22
Zhao, R., ZHOU, J., Chen, K., Gong, J., LIU, J., HE, J. Y., GUAN, P., LI, B., & QIN, Y. (2015) · Neoplasma · doi:10.4149/neo_2016_036 · Cited by 22
Hübner, J., Hoseini, S. S., Suerth, J. D., Hoffmann, D., Maluski, M., Herbst, J., Maul, H., Ghosh, A., Eiz‐Vesper, B., Yuan, Q., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.89 · Cited by 22
The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis
Chen, E., Zeng, Z., Bai, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10964 · Cited by 22
Lorente, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i37.4230 · Cited by 22
Lin, T., Zhu, Y., Li, Y., et al. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.04.007 · Cited by 22
Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia
Hutmacher, C., Volta, L. G., Rinaldi, F., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106178 · Cited by 22
Characterization of the prognostic values of CXCR family in gastric cancer
Yu, C., & Zhang, Y. (2019) · Cytokine · doi:10.1016/j.cyto.2019.154785 · Cited by 22
ZHAO, C., Setrerrahmane, S., & Han-mei, X. (2015) · Oncology Reports · doi:10.3892/or.2015.4163 · Cited by 21
Zhao, W., Luo, Y., Li, B., & Zhang, T. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5524 · Cited by 21
Hu, J., Feng, M. H., Liu, Z., Liu, Y., Huang, Z., Li, H., & Feng, W. (2016) · Tumor Biology · doi:10.1007/s13277-016-5413-3 · Cited by 21
Kakiuchi, S., Minami, Y., Miyata, Y., Mizutani, Y., Goto, H., Kawamoto, S., Yakushijin, K., Kurata, K., Matsuoka, H., & Minami, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030486 · Cited by 21
MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1
Gong, X.-F., Yu, A.-L., Tang, J., Wang, C.-L., He, J., Chen, G., Zhao, Q., He, M., & Zhou, C.-X. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.11.039 · Cited by 21
Ko, C., Li, C., Wu, M., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6794 · Cited by 21
What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?
Hayman, L., Chaudhry, W. R., Ревин, В. В., Zhelev, N., & Bourdon, J. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1563484 · Cited by 21
Yang, Z., Li, J., Shi, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.9889 · Cited by 21
Zhou, Y. N., Wen, P., Li, M., Li, Y., & Li, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10460 · Cited by 21
Vilchez, V., Turcios, L. M., Zaytseva, Y. Y., Stewart, R. L., Lee, E. Y., Maynard, E. C., Shah, M. B., Daily, M. F., Tzeng, C.-W. D., Davenport, D. L., et al. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2015.12.019 · Cited by 20
Shinohara, S., Hanagiri, T., Taira, A., Takenaka, M., Oka, S., Chikaishi, Y., Uramoto, H., So, T., Yamada, S., & Tanaka, F. (2016) · Oncology · doi:10.1159/000445951 · Cited by 20
Li, S., Huang, J. V., Zhou, X.-D., et al. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.06.01 · Cited by 20
Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy
Griffith, J. N., Andrade, D., Mehta, M., Berry, W. L., Benbrook, D. M., Aravindan, N., Herman, T. S., Ramesh, R., & Munshi, A. (2017) · Oncology Reports · doi:10.3892/or.2017.5478 · Cited by 20
Potential Role of OCT4 in Leukemogenesis
Picot, T., Kesr, S., Wu, Y., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2017.0134 · Cited by 20
The molecular signature of AML with increased ALDH activity suggests a stem cell origin
Blume, R., Rempel, E., Manta, L., Saeed, B. R., Wang, W., Raffel, S., Ermakova, O. V., Eckstein, V., Beneš, V., Trumpp, A., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1422862 · Cited by 20
LETM1 is a potential biomarker that predicts poor prognosis in gastric adenocarcinoma
Li, H., Piao, L., Xu, D., & Xuan, Y. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104333 · Cited by 20
Huang, X., Wan, J., Leng, D., et al. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8220 · Cited by 20
Cellular plasticity in the adult liver and stomach
Aloia, L., McKie, M. A., & Huch, M. (2016) · The Journal of Physiology · doi:10.1113/jp271769 · Cited by 19
Su, C., Xu, Y., Li, X., et al. (2015) · PubMed · Cited by 19
Myeloid leukemia with transdifferentiation plasticity developing from T‐cell progenitors
Riemke, P., Czéh, M., Fischer, J., Walter, C., Ghani, S., Zepper, M., Agelopoulos, K., Lettermann, S., Gebhardt, M. L., Mah, N., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201693927 · Cited by 19
Carrara, R. C. V., Fontes, A. M., Abraham, K., Orellana, M. D., Kashima, S. H., Palma, P. V. B., Panepucci, R. A., Zago, M. A., & Covas, D. T. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1751-x · Cited by 19
Thompson, J. C., Fan, R., Black, T. A., Yu, G. H., Savitch, S. L., Chien, A. L., Yee, S. S., Sen, M., Hwang, W., Katz, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.020 · Cited by 19
Therapeutic relevance of SOX9 stem cell factor in gastric cancer
Carrasco‐García, E., Álvarez‐Satta, M., García-Puga, M., Ribeiro, M. L., Arévalo, S., Araúzo-Bravo, M. J., & Matheu, A. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559826 · Cited by 19
Zamorano‐León, J. J., Ballesteros, S., Heras, N. D. L., Álvarez-Sala, L., de la Serna-Soto, M., Zekri-Nechar, K., Freixer, G., Rico, B. C., Yang, Z., García‐García, J. M., et al. (2019) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2019.24.2.187 · Cited by 19
Jun, S. Y., Jeon, S.-J., Yoon, J., Lee, J.-J., Yoon, H. R., Choi, M.-H., Halder, D., Lee, K. H., & Kim, N.-S. (2019) · Scientific Reports · doi:10.1038/s41598-019-53191-5 · Cited by 19
Wolf, B., Krieg, K., Falk, C. S., Breuhahn, K., Keppeler, H., Biedermann, T., Schmid, E., Warmann, S. W., Fuchs, J., Vetter, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3453 · Cited by 18
Self-citationGunaratna, R. T., Santos, A., Luo, L., Nagi, C. S., Lambertz, I. U., Spier, M. E., Conti, C. J., & Fuchs‐Young, R. (2019) · Oncogene · doi:10.1038/s41388-018-0630-4 · Cited by 18
Li, M., Tang, Y., Gong, Y., Cheng, W., Li, H., Kong, F.-E., Zhu, W., Liu, S., Huang, L., Guan, X., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6041-2 · Cited by 18
Molecular characterization of CD44+/CD24−/Ck+/CD45− cells in benign and malignant breast lesions
Paula, A. D. C., Leitão, C., Marques, O., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2068-4 · Cited by 17
Dai, X., Huang, T., Yang, S., Zheng, X., Chen, G. Y., & Zhang, T. (2017) · Disease Markers · doi:10.1155/2017/8495326 · Cited by 17
Tissue-based associations of mammographic breast density with breast stem cell markers
Yaghjyan, L., Stoll, E. M., Ghosh, K., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0889-3 · Cited by 17
Yang, L., Ding, C., Tang, W., Yang, T., Liu, M., Wu, H., Wen, K., Yao, X., Feng, J., & Luo, J. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz110 · Cited by 17
Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C
Wang, N.-S., Wei, M., Ma, W., Meng, W., & Zheng, W. (2013) · Tumor Biology · doi:10.1007/s13277-013-1523-3 · Cited by 16
KOYAMA, K., Katsurada, N., Jimbo, N., TACHIHARA, M. Y., Tamura, D., Nakata, K., Nagano, T., Yamamoto, M., Kamiryo, H., Kobayashi, K., et al. (2019) · Pathology International · doi:10.1111/pin.12782 · Cited by 16
Wu, J., Zhao, Y., Wu, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114746 · Cited by 15
Alama, A., Gangemi, R. M. R., Ferrini, S., et al. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0330-5 · Cited by 15
Kenderian, S. S., Ruella, M., Shestova, O. E., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.413 · Cited by 15
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
Miragaya, J. G., & González‐Suárez, E. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1338208 · Cited by 15
Fu, W., Sun, H., Zhao, Y., et al. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.05.010 · Cited by 15
Quan, Y. H., Lim, J.-Y., Choi, B. H., Choi, Y., Choi, Y. H., Park, J., & Kim, H. K. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3737-y · Cited by 15
Yaghjyan, L., Esnakula, A. K., Scott, C. G., et al. (2019) · Cancer Causes & Control · doi:10.1007/s10552-019-01207-w · Cited by 15
Morine, Y., Imura, S., Ikemoto, T., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.12007 · Cited by 15
Morise, M., Hishida, T., Takahashi, A., et al. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-1985-3 · Cited by 14
Distribution of Lgr5‐positive cancer cells in intramucosal gastric signet‐ring cell carcinoma
Nakajima, T., Uehara, T., Maruyama, Y., et al. (2016) · Pathology International · doi:10.1111/pin.12451 · Cited by 14
Detecting Markers of Therapy-Induced Senescence in Cancer Cells
Fan, D. N.-Y., & Schmitt, C. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6670-7_4 · Cited by 14
BMI-1 Promotes Self-Renewal of Radio- and Temozolomide (TMZ)-Resistant Breast Cancer Cells
Yan, Y., Wang, Y., Zhao, P., Ma, W., Hu, Z., & Zhang, K. (2017) · Reproductive Sciences · doi:10.1177/1933719117697255 · Cited by 14
Huang, Z., Yu, H., Zhang, J., et al. (2017) · Journal of Cancer · doi:10.7150/jca.20172 · Cited by 14
Zhou, J., Sun, J., Chen, H., & Peng, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4474 · Cited by 14
Bill, M., Aggerholm, A., Kjeldsen, E., Roug, A. S., Hokland, P., & Nederby, L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15711 · Cited by 14
Jiao, X.-L., Zhao, C., Niu, M., et al. (2013) · PubMed · Cited by 13
Notch3 negatively regulates chemoresistance in breast cancers
Gu, X., Lu, C., He, D., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5412-4 · Cited by 13
Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma.
Yu, G., Lin, X., Luo, R., et al. (2018) · PubMed · Cited by 13
Woodward, W. A., Krishnamurthy, S., Lodhi, A., et al. (2014) · Journal of Cancer · doi:10.7150/jca.7885 · Cited by 12
Huang, T., Qiu, X., Xiao, J., et al. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.07.009 · Cited by 12
Characterization of CD44+ALDH1+Ki-67– Cells in Non-malignant and Neoplastic Lesions of the Breast
Paula, A. D. C., Marques, O., Sampaio, R., Rosa, A. M., Garcia, J. P., Rêma, A., Faria, M. D. F., Silva, P., Vizcaino, J. R., & Lopes, C. (2016) · Anticancer Research · doi:10.21873/anticanres.11013 · Cited by 12
Portwood, S., Puchalski, R. A., Walker, R. M., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1645.1645 · Cited by 12
Koh, Y. W., Han, J., Haam, S., & Jung, J. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02906-2 · Cited by 12
Kongsgaard, A., Boye, K., Fodstad, Ø., et al. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0504-4 · Cited by 11
Kloeß, S., da Silva, A. E. V., Oberschmidt, O., Gardlowski, T., Matthies, N., Vyas, M., Arseniev, L., Heuser, M., von Strandmann, E. P., & Koehl, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01100 · Cited by 11
Kawano, Y., Iwama, E., Tsuchihashi, K., Shibahara, D., Harada, T., Tanaka, K., Nagano, O., Saya, H., Nakanishi, Y., & Okamoto, I. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.09.008 · Cited by 11
Zhao, Y., Wu, K., Wu, Y., et al. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467210666170919155739 · Cited by 11
Rossi, A., Voigtlaender, M., Klose, H. F. E., et al. (2019) · Journal of Oncology · doi:10.1155/2019/8970645 · Cited by 11
CD25 targeted therapy of chemotherapy resistant leukemic stem cells using DR5 specific TRAIL peptide
Madhumathi, J., Surapally, S., & Verma, R. S. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.01.001 · Cited by 10
Masamoto, Y., & Kurokawa, M. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.03.05 · Cited by 10
CD133 Expression as a Helicobacter pylori-independent Biomarker of Gastric Cancer Progression
Howard, R., Diffalha, S. A., Pimiento, J. M., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12746 · Cited by 10
Zhou, S., Zhu, X., Liu, W., Cheng, F., Zou, P., You, Y., Xiao, Y., Guo, A., & Zhu, X. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.092 · Cited by 10
Blaudszun, A., Moldenhauer, G., Schneider, M., & Philippi, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.10.025 · Cited by 9
Self-citationZhang, L., Yuan, Y.-Q., Zhou, D.-M., Wang, Z., Ju, S., Sun, Y.-H., Li, J., & Fu, J. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.1.431 · Cited by 9
Zhang, J., Zhao, A., Sun, L., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6336 · Cited by 9
Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining
Wen, G.-M., Mou, F.-F., Hou, W., Wang, D., & Pu, X. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9865-2 · Cited by 8
Smolle, E., Fink‐Neuboeck, N., Lindenmann, J., et al. (2019) · Cancers · doi:10.3390/cancers11081118 · Cited by 8
CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma
Sanmartín, E., Ortiz-Martínez, F., Pomares-Navarro, E., García‐Martínez, A., Rodrigo-Baños, M., García-Escolano, M., Andrés, L., Lerma, E., Aranda, I., Martínez-Peinado, P., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2045-3 · Cited by 7
The roles of CD133 expression in the patients with non-small cell lung cancer
Wang, D., Wen, G.-M., Hou, W., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170835 · Cited by 7
Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay
Rico, M. J., Perroud, H. A., Herrera, C., Alasino, C. M., Roggero, E., Pezzotto, S. M., Nocito, A. L., Rozados, V. R., & Scharovsky, O. G. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1309545 · Cited by 5
Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3
Homayouni, V., Khanahmad, H., Ganjalıkhani-Hakemi, M., et al. (2017) · Iranian Journal of Biotechnology · doi:10.15171/ijb.1427 · Cited by 5
Akamine, T., Tagawa, T., Ijichi, K., Toyokawa, G., Takamori, S., Hirai, F., Okamoto, T., Oda, Y., & Maehara, Y. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-018-07137-2 · Cited by 5
Liu, X., Wei, H., Liu, Y., et al. (2018) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2018.2562 · Cited by 4
Uncovering a new cellular origin for acute myeloid leukemia with lineage plasticity
Czéh, M., & Rosenbauer, F. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2016.1268241 · Cited by 3
The Role of Stem Cells in Breast Cancer
Zarzynska, J. M. (2017) · InTech eBooks · doi:10.5772/66904 · Cited by 3
Flagged first, then by citations
Research works printed but not linked: 1
- Berger, 2017, Das Rote Buch: Hämatologie und Internistische Onkologie, 1400
Cited by
Sorted by citations
Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Abd, G. M., Laird, M. C., Ku, J. C., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227884 · Cited by 41
CD166-specific CAR-T cells potently target colorectal cancer cells
He, S., Li, S., Guo, J., Zeng, X., Liang, D., Zhu, Y., Li, Y., Yang, D., & Zhao, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2022.101575 · Cited by 30
Shuvalov, O., Kirdeeva, Y., Fefilova, E., Netsvetay, S., Zorin, M., Vlasova, Y., Fedorova, O., Daks, A., Parfenyev, S., & Barlev, N. (2023) · Metabolites · doi:10.3390/metabo13050656 · Cited by 21
Metadata
- Authors
- Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U.
- Affiliations
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Yevsa, Tetyana
- Kossatz-Boehlert, Uta
- ORCID
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-07
- Volume
- 11
- Pages
- 1280-1280
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC7426526
- OpenAlex
- W3047693299
- Cited by
- 1,007
- References
- 603
- Citations by year
- 2026: 75 · 2025: 177 · 2024: 284 · 2023: 244 · 2022: 170 · 2021: 52 · 2020: 5
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) (submittedVersion, other-oa)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (YE 151/2-1, AOBJ: 618426)
- Fraunhofer-Gesellschaft
- Fritz Thyssen Stiftung (REF.10.16.1.031MN)
- Sächsische Aufbaubank
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Keywords
- cancer stem cells, tumor recurrence, senescence-associated secretory phenotype, senescence escape, tumor microenvironment, chemoresistance, radiotherapy, chimeric antigen receptor T cells, precision oncology, acute myeloid leukemia, chronic myeloid leukemia, solid tumors, hematologic cancer
- MeSH terms
- Animals, Combined Modality Therapy, Disease Susceptibility, Humans, Neoplasms, Organ Specificity, Prognosis, Biomarkers, Tumor, Neoplastic Stem Cells, Biomarkers, Immunotherapy, Adoptive, Cellular Senescence, Disease Progression, Drug Resistance, Neoplasm, Disease Management, Molecular Diagnostic Techniques, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
